Trial Profile
Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Clofarabine (Primary) ; Thiotepa (Primary) ; Antithymocyte globulin; Cyclophosphamide; Filgrastim; Mesna; Methotrexate; Tacrolimus
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
- 22 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.